Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could AI chatbots hook the brains already vulnerable to addiction?

NCT ID NCT07819851

Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Nice Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 15, 2026 · Last updated Sep 16, 2026 · Updated 1 time

Summary

Researchers in France ask whether adults treated for substance use disorder also depend more heavily on conversational AI tools. About 100 outpatients at specialized addiction centers fill out one 15-minute questionnaire covering their AI use and their DSM-5 substance use criteria. The team then compares the two scores and reviews medical records for psychiatric conditions. The study measures a possible link; it does not test a treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If a link appears, it could help clinicians recognize problematic AI use in people already treated for addiction and shape screening questions for digital dependence.
What could go wrong
This is a one-time questionnaire study of about 100 people in French addiction clinics, so it can show a pattern but not prove that one problem causes the other, and the findings may not apply to other groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patient (aged 18 years or older), with or without legal protection measures * Actively followed for a substance use disorder (SUD) characterized according to DSM-5 criteria at a participating specialized addiction care center (Nice University Hospital or Sainte-Marie Hospital in Nice, France). * Self-reported use of a conversational generative artificial intelligence tool at least once in the past 12 months. * Ability to understand, read, and complete a self-administered questionnaire in French. * Oral non-opposition obtained from the patient (and from their legal representative if applicable). * Affiliated with or beneficiary of a French social security healthcare system. Exclusion Criteria: * Minor patient (\< 18 years old). * Major neurocognitive disorders, intellectual disability, or acute psychiatric decompensation precluding comprehension or questionnaire completion. * Explicit opposition to participate expressed by the patient or their legal representative. * Withdrawal of non-opposition during the study. * Incomplete questionnaire or clinical record preventing computation of primary scores.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Artificial intelligence (AI) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Behavior, Addictive substance-related disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Artificial intelligence (AI) Behavior, addictive Substance-related disorders

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU de Nice

    Nice, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.